Allspring Global Investments Holdings LLC Sells 266,856 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Allspring Global Investments Holdings LLC reduced its position in shares of Chimerix, Inc. (NASDAQ:CMRX – Get Rating) by 42.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 356,812 shares of the biopharmaceutical company’s stock after selling 266,856 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Chimerix were worth $688,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Chimerix by 9.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 50,825 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 4,209 shares during the period. Prelude Capital Management LLC boosted its holdings in shares of Chimerix by 2.9% during the 2nd quarter. Prelude Capital Management LLC now owns 149,179 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 4,262 shares during the period. Credit Suisse AG boosted its holdings in shares of Chimerix by 1.9% during the 2nd quarter. Credit Suisse AG now owns 321,013 shares of the biopharmaceutical company’s stock worth $667,000 after buying an additional 5,847 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Chimerix by 77.1% during the 2nd quarter. Principal Financial Group Inc. now owns 20,007 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 8,710 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Chimerix by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 108,736 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 9,225 shares during the period. 58.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, Chimerix has a consensus rating of “Buy” and an average price target of $8.50.

Chimerix Price Performance

Shares of Chimerix stock opened at $1.83 on Monday. Chimerix, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $6.43. The firm has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.08. The company has a market cap of $161.12 million, a PE ratio of 1.05 and a beta of 1.17.

Chimerix (NASDAQ:CMRX – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.10 by $0.65. Chimerix had a net margin of 464.75% and a return on equity of 147.04%. The firm had revenue of $32.56 million during the quarter, compared to the consensus estimate of $205.30 million. Analysts expect that Chimerix, Inc. will post 1.97 earnings per share for the current fiscal year.

About Chimerix

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.